In brief: Amazon One Medical’s new partner, OIG’s new report, AASM’s new guidelines

AVON, Ohio – Amazon One Medical and Cleveland Clinic are expanding access to primary care in Northeast Ohio with the opening of the first of two planned offices in the region. 

This first office in Avon, Ohio, will be followed with a second office in Shaker Heights, Ohio, by January 2026. 

“Primary care helps patients lead healthier lives,” said Pooja Kamath, MD, medical director of Cleveland Offices, One Medical. “We can prevent many health problems before they ever occur. We’re excited to bring our services to our Northeast Ohio community.” 

The new One Medical primary care office will provide Northeast Ohio residents with comprehensive health care services, including preventive screenings that can detect health issues early, management of chronic conditions like diabetes and hypertension, and accessible care for immediate concerns like cold and flu. 

Combining an innovative care model with a high-quality network 

The collaboration between One Medical, a national in-person and virtual primary care organization, and Cleveland Clinic, a 6,690-bed health system that includes 23 hospitals and 276 outpatient facilities, will enable patients to have increased access to seamless coordinated care through One Medical's innovative care model and Cleveland Clinic's high-quality network, they say.  

"Access to quality health care is important for maintaining good health, as well as preventing and managing disease," said James Gutierrez, M.D., chief of Cleveland Clinic’s Primary Care Institute. "We are proud to collaborate with Amazon One Medical to expand access to essential health services across Northeast Ohio. This new location in Avon strengthens the primary care options available to our communities while complementing Cleveland Clinic’s specialty care expertise and its existing primary care practices.” 

About One Medical 

While not required for scheduled in-person or remote appointments, One Medical memberships can be added as a Prime benefit for Amazon Prime members at health.amazon.com/prime for $9/month or $99/year, or purchased at OneMedical.com. Membership covers access to One Medical’s 24/7 on-demand virtual care services, including video chats with licensed providers within minutes, that lets members get fast care for common concerns such as allergies, skin issues, urinary tract infections and more. One Medical accepts many major insurance plans for in-person care or pre-scheduled remote visits. 

One Medical also works with more than 10,000 employers across all sizes and industries throughout the U.S. who sponsor membership fees as a benefit for their employees and their dependents. 

In addition to the new Cleveland-area office, One Medical has offices in more than 20 U.S. regions. 

Report: Sleep and oxygen therapy trends show mixed outlook for growth 

NEW YORK – Respondents saw improved sleep patient volume growth in the last 12 months, but they expect slower growth in the next 12 months, according to the 3Q25 HME Sleep and Oxygen Survey from Needham. 

Respondents saw their sleep patient volume increase by an average of 8.8% in the last 12 months (vs. 3.4% in the prior survey) and expect it to increase by 6.6% in the next 12 months (vs. 7.2% in the prior survey). 

Other highlights from the survey: 

Respondents are seeing a small loss of sleep patients from GLP-1 drugs. While 80% of respondents indicated they were unsure how many of their sleep patients were on GLP-1 drugs, the remaining 20% estimated that an average of 6.2% of their patients were on the drug. Of their overall sleep patients, respondents reported that 2.1% had stopped using CPAP therapy. 

Resmed looks likely to lose flow generator and mask market share over the next 12 months, despite having the highest rated flow generators and masks. Respondents expect Resmed's share of flow generator purchases to decrease 9.3% from 79.3% to 70% and its share of their mask purchases to decrease by 2.7% from 50.2% to 47.5% over the next 12 months. 

Respondents were also asked how their flow generator mix would change if Philips Respironics relaunched its flow generators with unlimited supply. Respondents indicated that their average flow generator mix would be 49.6% Resmed, followed by Philips Respironics at 25%, React Health at 16.5%, and other companies at 8.9%. 

Resmed had the highest-rated flow generators, nasal masks, nasal pillow masks and full-face masks. 

Flow generated prices saw the first decline in many years, while mask price increases improved slightly. Respondents reported that flow generator prices decreased by 0.4% in the last 12 months (vs. 0.9% increase in the prior survey). They reported that mask prices increased by 3% (vs. 2.9% in the prior survey). 

For home oxygen therapy: 

• Respondents saw their oxygen patient volume increase by an average of 1.6% in the past 12 months (vs. 1.3% in the prior survey) and expect it to increase by 3.3% in the next 12 months (vs. 5.6% in the prior survey). 
• Respondents expect Inogen and OxyGo’s combined share of portable oxygen concentrator (POC) purchases to decrease by 2.5% from 43.6% to 41.1%. Rhythm Healthcare had the highest rated POCs, followed by OxyGo and Inogen. 

The report was based on 16 completed surveys. 

OIG: Medicare paid $22.7M in improper payments for DMEPOS 

WASHINGTON - Medicare made $22.7 million in improper payments to suppliers for DMEPOS items provided to enrollees during inpatient stays that did not comply with requirements, according to a new report from the Office of Inspector General (OIG). 

The OIG also found suppliers may have incorrectly collected up to $5.9 million in deductible and coinsurance amounts from enrollees or from someone on their behalf. 

Additionally, the OIG found that system edits were not working properly prior to January 2020 and after CMS modified the edits in January 2020, improper payments substantially decreased. From January 2020 through December 2024, $4.5 million was improperly paid (about 20% of the $22.7 million). Because improper payments continue to be made, the OIG says further review of the edits may be necessary to determine whether refinements are needed. 

The OIG made five recommendations, including that:  

• CMS direct the DME Medicare contractors to recover from suppliers up to $22.7 million in identified improper payments and recommend that the suppliers refund to enrollees up to $5.9 million in deductible and coinsurance amounts. 
• CMS review its system edits to determine whether any refinements are necessary to prevent improper payments to suppliers for DMEPOS items provided to enrollees during inpatient stays.  

CMS concurred with four recommendations. CMS did not concur with the recommendation to review system edits. 

FDA warns Philips of violations at facilities making ultrasounds, medical systems 

WASHINGTON – The U.S. Food and Drug Administration (FDA) has sent Royal Philips CEO Roy Jakobs a warning letter saying the devices made at three of its facilities are adulterated and fail to conform with current good manufacturing practice requirements. The facilities are: 

• Philips Ultrasound in Bothell, Wash.; 
• Philips Ultrasound in Reedsville, Pa.; and 
• Philips Medical Systems in Eindhoven, the Netherlands 

The FDA outlined nine violations, including: 

• Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. 
• Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. 
• Failure to establish and maintain procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. 
• Failure to establish and maintain procedures for implementing corrective and preventive action (CAPA), including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. 

Philips told Bloomberg it took the warning very seriously, and it has responded to the FDA. The company also told Bloomberg the products mentioned in the FDA’s letter continue to be manufactured and sold, and it does not expect any material commercial impact from the warning. 

AASM releases new central sleep apnea guidelines 

DARIEN, Ill. – A new clinical practice guideline developed by a task force of the American Academy of Sleep Medicine provides updated recommendations for the treatment of central sleep apnea. The guideline, published in Journal of Clinical Sleep Medicine, updates AASM’s previous practice parameters published in 2012 and 2016. Among other significant updates, it incorporates evidence from recent studies of adaptive servo ventilation and addresses new developments, including the introduction of transvenous phrenic nerve stimulation as a novel therapy. “Central sleep apnea is a complex form of sleep-disordered breathing that requires individualized, patient-centered care,” said lead author Dr. M. Safwan Badr, chair of the AASM task force and chair of the department of internal medicine at Wayne State University School of Medicine in Detroit. “It is essential for the treating clinician to prioritize improvements in quality of life and functional outcomes rather than focusing exclusively on the elimination of disordered breathing events.” The guidelines make nine clinical recommendations designated as “conditional,” meaning that they reflect a lower degree of certainty and require the clinician to use clinical judgment while considering the patient’s values and preferences to determine the best course of action. These recommendations support six treatment options for specific etiologies of central sleep apnea: continuous positive airway pressure, bilevel positive airway pressure with a backup rate, adaptive servo ventilation, low-flow oxygen, oral acetazolamide, and transvenous phrenic nerve stimulation. The guideline states that clinicians must consider the underlying condition contributing to breathing instability when selecting and optimizing therapy for central sleep apnea. This guideline was endorsed by the Alliance of Sleep Apnea Partners, American Association for Respiratory Care, American Association of Sleep Technologists, Australasian Sleep Association, European Respiratory Society, European Sleep Research Society, Heart Failure Society of America, Society of Anesthesia and Sleep Medicine, and the Society of Behavioral Sleep Medicine.  

OMRON honored for its IntelliSense AFib devices 

HOFFMAN ESTATES, Ill. - The Digital Health Hub Foundation 2025 Digital Health Awards recognized OMRON Healthcare as a Best in Class Winner in the Home Health Diagnostics & Monitoring category for its breakthrough blood pressure monitors with IntelliSense AFib detection. The monitors automatically screen for atrial fibrillation during every blood pressure measurement and can provide early detection of elevated risk for a high stroke, heart failure and dementia risk. "Our OMRON Healthcare team is thrilled to accept this Best in Class Digital Health Award," said Alice Koehler, managing director of OMRON Healthcare North America. "The digital health category is rapidly maturing and there was a record-setting number of entrants in the competition this year. Thank you to the judges for recognizing our achievement in innovation that empowers people to take charge of their health."  

HOMELINK welcomes Schroeder as VP of managed care 

WATERLOO, Iowa – HOMELINK has named Allan Schroeder as vice president of managed care. In one of his previous roles, Schroeder led the development of an extensive suite of services in the workers’ compensation space, including clinical review programs, care coordination support and bill review solutions. “Allan brings a great combination of strategic insight and operational expertise that will strengthen our clinical capabilities,” said Danny Real, chief revenue officer at HOMELINK. “His leadership will play a key role in advancing our care delivery approach and enhancing the value we bring to our clients.” Shroeder’s background also includes executive roles in revenue cycle management, as well as radiology and teleradiology services. Earlier in his career, he held various general counsel positions, all health care related. “Joining HOMELINK is an exciting opportunity to contribute to a company that’s redefining how ancillary care services are delivered,” Schroeder said. “I look forward to helping accelerate that momentum and deliver solutions that truly make a difference for our clients and the injured workers they serve.” 

Tandem’s t:slim integrates with FreeStyle Libre 3 Plus 

SAN DIEGO – Tandem Diabetes has announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States. This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes worldwide, the company says. “With this integration, we expand the benefits of greater control to more people living with diabetes worldwide with our AID system that is easy to start, use, and personalize,” said John Sheridan, president and CEO. “It combines Control-IQ+, our most advanced algorithm ever, together with the benefits of Abbott’s latest CGM sensor on our tested and trusted t:slim X2 insulin pump.” In the U.S., the updated software for the FreeStyle Libre 3 Plus sensor integration is preloaded on all new t:slim X2 pump shipments, and is also available to all eligible t:slim X2 pump users through a software update. The company plans to launch early-access programs for the integrated technologies internationally before the end of the year, with scaling commercial availability to follow in 2026.  

NHIA opens registration for 2026 conference 

ALEXANDRIA, Va. — Registration is now open for the National Home Infusion Association's 2026 Annual Conference April 18-22, 2026, at the Gaylord Rockies Resort and Convention Center in Denver. NHIA 2026 will feature four days of educational content on topics selected for their relevance by industry-leading experts, drawing from more than 150 industry submissions on the most current practices and trends. "NHIA continues to elevate and evolve the conference based on industry trends and needs while also maintaining the high-quality education and intimate atmosphere attendees appreciate," said NHIA President and CEO Connie Sullivan. "This year, we are introducing dynamic new education formats with more interactivity, as well as facilitated networking experiences woven throughout the program. We've also enhanced our leadership education to complement our continuing commitment to world-class clinical, revenue cycle, operations, and executive education." NHIA 2026 offers more than 40 hours of CE for pharmacists, pharmacy technicians, nurses and dietitians, as well as networking opportunities strategically placed throughout each day. Additionally, three keynote sessions will offer powerful takeaways related to personal and professional success; a high-level industry outlook; and leadership education. Companies can learn more about exhibiting at or attending NHIA's 2026 Annual Conference, by visiting conference.nhia.org. 

RESNA welcomes three new board members 

WASHINGTON – RESNA has three new board members: Cara Masselink, Julie Brown and Stephanie Bay. The organization has also re-elected Ana Allegretti for a second term. RESNA elected Masselink and Brown to three-year terms, starting Aug. 1, 2025. It elected Bay as a presidential appointee with a one-year term. FMI: 

• Cara Masselink, formerly executive director of The Clinician Task Force, and Occupational Therapy, Western Michigan University 
• Julie Brown, PT, DPT, NCS, ATP/SMS, Bryn Mawr Rehabilitation, Inpatient and Outpatient Rehabilitation 
• Stephanie Bay, clinical assistant professor, Department of Disability and Human Development, University of Illinois-Chicago 

For a full list of RESNA’s board members, go here. 

Humotech launches clinical pilot with ēlizur 

PITTSBURGH, Pa. – Humotech, a Pittsburgh-based pioneer in wearable robotics and mobility innovation, has launched a clinical pilot with ēlizur, a leading orthotics and prosthetics (O&P) provider. Debuting this fall, the initiative will bring Humotech’s Caplex System into clinical practice, giving patients the ability to “test drive” prosthetic feet before prescription – an approach poised to redefine the future of prosthetic care, the company says. By combining ēlizur’s patient-centered expertise with Humotech’s advanced clinical decision support technology, the pilot will empower clinicians to make more informed, data-driven decisions and help patients achieve better outcomes faster, it says. “I believe this patient-centric technology will create a more efficient and appropriate prosthetic foot selection process for both the patient and the prosthetist,” said Brad Scott, director of Prosthetics & Orthotics at ēlizur. “Patients will spend less time in the clinic while being matched with the most biomechanically suitable foot. Meanwhile, practitioners will no longer have to juggle ordering and returning multiple feet from manufacturers. I also believe this technology will provide strong medical justification when obtaining a new foot for a patient transitioning from their preparatory prosthesis to their definitive one.”